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Abstract
Background: The pro-tumorigenic effects of the insulin-like growth factor receptor (IGF1R) are well described.
IGF1R promotes cancer cell survival and proliferation and prevents apoptosis, and, additionally it was shown that
IGF1R levels are significantly elevated in most common human malignancies including breast cancer. However,
results from phase 3 clinical trials in unselected patients demonstrated lack of efficacy for anti-IGF1R therapy. These
findings suggest that predictive biomarkers are greatly warranted in order to identify patients that will benefit from
anti-IGF1R therapeutic strategies.
Methods: Using the delivery of shRNA vectors into the Mvt1 cell line, we tested the role of the IGF1R in the
development of mammary tumors. Based on CD24 cell surface expression, control and IGF1R-knockdown
(IGF1R-KD) cells were FACS sorted into CD24− and CD24+ subsets and further characterized in vitro. The
tumorigenic capacity of each was determined following orthotopic inoculation into the mammary fat pad of
female mice. Tumor cells were FACS characterized upon sacrifice to determine IGF1R effect on the plasticity of this
cell’s phenotype. Metastatic capacity of the cells was assessed using the tail vein assay.
Results: In this study we demonstrate that downregulation of the IGF1R specifically in cancer cells expressing
CD24 on the cell surface membrane affect both their morphology (from mesenchymal-like into epithelial-like
morphology) and phenotype in vitro. Moreover, we demonstrate that IGF1R-KD abolished both CD24+ cells
capacity to form mammary tumors and lung metastatic lesions. We found in both cells and tumors a marked
upregulation in CTFG and a significant reduction of SLP1 expression in the CD24+/IGF1R-KD; tumor-suppressor
and tumor-promoting genes respectively.
Moreover, we demonstrate here that the IGF1R is essential for the maintenance of stem/progenitor-like cancer cells
and we further demonstrate that IGF1R-KD induces in vivo differentiation of the CD24+ cells toward the CD24-
phenotype. This further supports the antitumorigenic effects of IGF1R-KD, as we recently published that these
differentiated cells demonstrate significantly lower tumorigenic capacity compared with their CD24+ counterparts.
Conclusions: Taken together these findings suggest that CD24 cell surface expression may serve as a valuable
biomarker in order to identify mammary tumors that will positively respond to targeted IGF1R therapies.
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Background
The insulin-like growth factor receptor (IGFIR) is a
transmembrane receptor tyrosine kinase [1] that is
primarily activated by its cognate ligands, IGF1 and
IGF2, and can be activated by insulin albeit with much
lower affinity [2]. Since the early 1980s, when interest in
IGF1R’s role in breast cancer development began [3, 4],
preclinical studies demonstrated that IGF1R is involved
in cell transformation in addition to mediating tumor-
promoting functions such as proliferation, antiapoptosis
and cancer cell dissemination [5–7]. Case control and
prospective studies further supported the role of the
IGF1R axis in breast cancer patients [8]. This repertoire
placed IGF1R as a promising target for cancer therapy.
However, recent results from clinical trials indicated that
IGF1R antagonists failed to fulfill the high expectation
[9, 10]. It has now become clear that predictive biomarkers
are warranted in order to identify patients that will benefit
from anti-IGF1R therapy.
Recently, based on CD24 cell surface expression we
were able to distinguish, sort and maintain two distinct
subpopulations of the metastatic mammary carcinoma
cell line, Mvt1 that overexpresses the c-Myc and VEGF
oncogenes [11]. CD24 is an anchored cell surface
glycoprotein, mainly associated with the progression
of invasive tumors through P-selectin binding, which is
expressed by activated endothelial cells and platelets
[12, 13]. More recently, it was shown that intracellular
CD24 promotes tumorigenesis by the distribution of the
ARF-NPM interaction and p53 inactivation [14]. Further-
more, it was shown that CD24 can serve as an important
indicator for poor prognosis for many of the most
common malignancies including breast cancer [15, 16].
Our recently published results demonstrated that
CD24+ cells displayed more spindle-like cells that resem-
ble a mesenchymal phenotype compared to the rounded
epithelial morphology of their CD24− counterparts.
Moreover, CD24+ cells displayed highly tumorigenic and
metastatic properties in vivo. Implantation of CD24+
cells into the mammary fat pad of FVB/N female mice
and the hyperinsulinemic MKR female mice resulted in
more rapidly growing tumors. Furthermore, this CD24+
subset formed metastatic lesions at a higher rate from
both primary tumors and following tail vein injection.
CD24 is widely used to isolate pure mammary epithelial
cells and along with other cell surface markers it can
further serve to isolate stem/progenitor cells. It was shown
that Lin-CD24+CD49f murine mammary cells were able to
generate in vivo functional mammary tissue [17, 18]. In
accordance with these findings, we have demonstrated
that CD24+ cells possess cancer stem/progenitor-like
properties both in vitro and in vivo. These cells are driven
to differentiate in vivo and partly account for intratumor
heterogeneity [19]. Whereas CD24 can serve in certain
cases as a marker for stemness, the IGF1R was found to
play a crucial role in maintaining pluripotent properties of
human embryonic stem cells [20]; the self-renewal
property of cancer stem cells [21].
In this study, we determined whether the cell surface
expression of CD24 may serve as a valuable biomarker
for tumor sensitivity to anti-IGF1R therapy. To begin to
elucidate this issue we compared the effects of the
IGF1R-knockdown (KD) on CD24- and CD24+ cells
morphology and phenotype in vitro. Moreover, we
compared the tumorigenic and metastatic capacity in
vivo of these distinct subsets following IGF1R-KD. We
further screened for transcripts that may illuminate
on the discrepancy in the effects obtained between these
subsets. Finally, we tested the feasibility of the results
on the human mammary cancer MCF7 cell line.
We anticipate that this study may constitute the
starting point for future attempts to clinically circumvent




Mouse and human mammary cancer cell lines, Mvt-1,
and MCF7 cell line have been previously described
[22, 23]. Cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM; Biological Industries, Beit
Haemek, Israel) supplemented with 10 % fetal bovine
serum (FBS) (Biological Industries) and antibiotics
(penicillin:streptomycin; Biological Industries) at 37 °C
in a humidified atmosphere consisting of 5 % CO2
and 95 % air.
Knockdown of IGF1R and IR by lentiviral-based delivery
of shRNA
Vectors (GIPZ) encoding the following microRNA-
adapted short hairpin RNAs (shRNA) 5’-TGACTGT
GAAATCTTCGGC-3’ (mouse/human IGF1R), 5’- TTA
GTTCCATGATGACCAG-3’ (mouse IGF1R) packed in
high-titer lentiviral particles were purchased from Open
Biosystems (Huntsville, AL, USA). These vectors or a
vector containing a scrambled shRNA sequence (control
shRNA; Open Biosystems) were infected in the presence
of 8 μg/ml polybrene (Sigma-Aldrich, Rehovot, Israel) into
Mvt-1 or MCF7 cells, all three vectors contained a green
fluorescent protein (GFP) marker and puromycin resist-
ance gene. Stable knockdown of the IGF1R was achieved
by selection with 2 μg/ml puromycin (Sigma-Aldrich).
Protein extraction and Western blot analysis
Western blot and densitometric analysis was carried out
for protein detection in cells and tumor tissues as previ-
ously described [24]. Antibodies toward IGF1R and β-actin
were purchased from Cell Signaling Technology, Danvers,
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MA, USA, antibody toward SLPI was purchased from
Thermo Fisher Scientific, Rockford, IL, USA, and the
matched secondary antibody conjugated with horseradish
peroxidase was purchased from Jackson Laboratories, Bar
Harbor, ME, USA.
Animals
Female MKR mice and control mice on an FVB/N back-
ground were used in this study. The MKR mice are
transgenic mice with a dominant-negative insulin-like
growth factor-I receptor specifically targeted to the
skeletal muscle, with a resultant severe insulin resistance
and hyperinsulinemia phenotype [25]. Mice were kept
on a 12-hour light/dark cycle with access to standard
mouse chow and fresh water ad libitum. Mice studies
were performed according to the protocol approved by
the Technion Animal Inspection Committee. The Tech-
nion holds a National Institutes of Health (NIH) animal
approval license number A5026-01.
Syngeneic orthotopic tumor models
CD24- and CD24+ cells or knockdown cells were sus-
pended in 100 μl phosphate-buffered saline (PBS) and
then injected (5 × 104 cells/mouse, fewer cells were
injected for the serial dilution experiments) into the left
inguinal mammary fat pad (number 4) of 8-week-old
female MKR mice. Tumor volume was monitored once a
week with calipers and the volume was calculated in mm3
by the formula: (width2 × length × 0.5). Following sacrifice,
tumors were removed and weighed, then flash frozen in
liquid nitrogen and kept at -80 for further analysis.
Flow cytometry
Pacific Blue-conjugated anti-mouse CD24 or PerCP/
Cy5.5-conjugated anti-human CD24 (Biolegend, San
Diego, CA, USA) were used for cell surface staining of
the cells. 7-amino actinomycin D (7-AAD, Biolegend)
was used to gate live cells. Cells were stained at a con-
centration of 5 × 106 cells/ml of fluorescence-activated
cell sorting (FACS) buffer (PBS containing 0.1 % bovine
serum albumin [BSA]) for 20 minutes on ice in the dark,
after which, the cells were washed twice and resus-
pended in FACS buffer containing 7-AAD. Stained cells
were analyzed using the CyAn ADP Instrument (Dako-
Cytomation, Glostrup, Denmark) and the FlowJo 7.25
analysis software (Tree Star, Ashland, OR, USA). Flow
cytometry-based cell sorting for CD24- IGF1R-KD and
CD24+ IGF1R-KD cells was performed using FACSAria
(BD Biosciences, San Jose, CA, USA).
Tumorspheres
CD24- IGF1R-KD and CD24+ IGF1R-KD cell suspensions
were prepared and plated in nonadherent conditions at
600 cells/cm2 in DMEM F12 HAM medium (Sigma-
Aldrich, Rehovot, Israel) containing 20 ng/ml basic fibro-
blast growth factor (bFGF) (Sigma-Aldrich), 20 ng/ml epi-
dermal growth factor (EGF) (Sigma-Aldrich), 4 μg/ml of
heparin (Sigma-Aldrich) and B-27 supplement (1:50 dilu-
tion, GIBCO, Burlington, ON, Canada), and cultured at 37
degree with 5 % CO2. Tumorsphere-forming efficiency
(TFE) (%) was calculated after 5 days as follows: (number
of tumorspheres (>50 mm in diameter) per well/number
of cells seeded per well)*100. In order to assess self-
renewal, primary tumorspheres were centrifuged at 115 ×
g for 5 minutes; the pellet was resuspended in 300 μl of
0.5 % trypsin/0.2 % EDTA for 3 min at 37 °C. Tumor-
spheres were disaggregated into single cell suspension
with the use of a 25 G needle and syringe, (trypsin was
neutralized with medium containing serum). Cells were
centrifuged at 580 × g for 5 min, the pellet was resus-
pended in ice-cold PBS, and single cell suspension was as-
sured under a microscope. Single cells were plated at the
same seeding density that was used in the primary gener-
ation. Following 5 days in culture tumorspheres (>50 mm
in diameter) were measured.
Quantitative PCR reaction for cDNA products
Quantitative PCR was performed using Absolute Blue
SYBR-Green ROX mix (Thermo Fisher Scientific, ABgene,
Epsom, UK). RNA was extracted from treated Mvt-1 cells
with the Total RNA Purification Kit (NORGEN Biotek
Corp, Thorold, Canada) according to manufacturer's in-
structions, followed by single-stranded cDNA synthesis
using the Verso™ reverse transcriptase (Thermo Fisher
Scientific, ABgene). The expression measurement of the
designated genes was performed with the Rotor-GeneTM
6000 system (Corbett Research, Sydney, Australia) and its
software, ver. 1.7. The relative gene copy number was
normalized using B2M as independent internal control
gene, and calculated by the 2^-(Ct(n)-Ct(normalizer)) method.
Tumor dissociation into single cells
Breast tumors were minced with scalpels and transferred
to gentleMACS™ dissociator C-tubes (Miltenyi Biotec,
Bergisch Gladbach, Germany) containing 5 ml of DMEM
medium (Biological Industries, Beit Haemek, Israel) sup-
plemented with 10 % FBS (Biological Industries). C-tubes
were then connected to the gentleMACS™ dissociator and
tumor dissociation was performed according to the manu-
facturer’s instructions. Minced tumors were incubated in
the C-tubes for 45 min with 300 unit/ml collagenase I
(Sigma-Aldrich, Rehovot, Israel) and 2 mg/ml dispase II
(Roche Diagnostics, Mannheim, Germany) at 37 °C in a
humidified atmosphere consisting of 5 % CO2 and 95 %
air. Following incubation a second spin on the gentle-
MACS™ dissociator was performed, and the cells were
then filtered through a 40-μm falcon strainer (Becton
Dickinson, Franklin Lakes, NJ, USA).
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Tail vein metastasis assay
A total of 10,000 cells from each subset were injected
through the tail vein of WT mice to assess lung metastatic
activity. Mice were sacrificed 28 days following injection,
lungs were removed and fixed, macrometastases were
counted under the light microscope.
Statistical analysis
All data are presented as mean ± standard error of the
mean (SEM). Independent t test and the Mann-Whitney
test was used for statistical analysis of unmatched
groups; the Wilcoxon signed-rank test was used for
matched group comparison, with P values < 0.05 consid-
ered statistically significant.
Results
CD24+ cells demonstrate significantly higher levels of the
IGF1R
In order to investigate the role of the IGF1R in tumori-
genesis, we first downregulated the IGF1R in the Mvt1
cell line. IGF1R was downregulated by approximately
88 % as determined by Western blot analysis (Fig. 1a, b).
Recently, we and others demonstrated that the efficacy
of targeting IGF1R alone in cancer is limited [11, 26].
Here, we confirmed these results, as mammary tumors
initiated by IGF1R-KD cells developed only slightly, but
not significantly, slower compared to the control tumors
in female FVB/N mice (Fig. 1c). CD24 expression serves






























































Fig. 1 CD24+ cells demonstrate significantly higher levels of the IGF1R. a Western blot analysis of IGF1R expression in Mvt1 cells infected with
control or IGF1R shRNA as indicated. b Protein expression was quantified relative to β-actin expression by densitometric analysis. c Control and
IGF1R-KD cells were injected into the fourth mammary fat pad of 8-week-old virgin female FVB/N mice (50,000 cells/mouse) and tumor volume
was measured during a 5-week period. d Western blot analysis of IGF1R expression in CD24- and CD24+ Mvt1 cells. e Protein expression was
quantified relative to β-actin expression by densitometric analysis. The Mann-Whitney test was performed to compare the difference in IGF1R
between CD24+ and CD24+ cells ***P < 0.001. IGF1R insulin-like growth factor receptor, KD knockdown
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[15], and we have recently demonstrated that CD24+
Mvt1 cells are highly tumorigenic compared with their
CD24- counterparts [19]. We therefore examined IGF1R
levels in each of these subpopulations. Western blot
analysis revealed significantly elevated IGF1R levels
(>1.8-fold) in the aggressive CD24+ cells compared
with the CD24- subset (Fig. 1d, e).
IGF1R-KD has a profound effect on CD24+ cells
morphology and phenotype
In order to test the effect of IGF1R-KD in each subset
(CD24- and CD24+ cells), control and IGF1R-KD cells
were double sorted into pure (>95 % as determined by
FACS analysis) CD24- and CD24+ subpopulations (Fig. 2a).
In accordance with our recent publication [19] CD24+
control cells displayed distinct morphology in adherent
conditions compared to their CD24- counterparts. CD24+
are larger cells with spindle-like cytoplasm compared to
the more rounded-epithelial CD24- control cells (Fig. 2b).
Whereas IGF1R-KD had no effect on the CD24- cell
morphology, the CD24+ IGF1R-KD cells appeared to have
a more epithelial morphology, similar to the CD24- cells
and distinct from the CD24+ control cells (Fig. 2b).
Using the tumorsphere assay we demonstrated that
CD24+ Mvt-1 cells possess cancer stem-like cells charac-
teristics [19], and we tested whether this phenotype is
IGF1R-dependent. Cells were cultured in nonadherent
conditions in serum-free optimized medium. As expected,
CD24+ control cells displayed high tumor-forming effi-
ciency. No tumorspheres were detected in the CD24-
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Fig. 2 IGF1R-KD has a profound effect on CD24+ cells morphology and phenotype. a FACS histograms of control and IGF1R-KD Mvt-1 cells following
sorting into pure CD24- and CD24+ cell populations. b Cell phenotype in adherent culture for each group is presented in a phase-contrast bright field
image. c Representative photomicrographs of tumorsphere (> 50 um diameter) grown from single cells in nonadherent culture for 5 days (upper panel).
TFE (%) comparison between the groups (lower panel). IGF1R insulin-like growth factor receptor, KD knockdown, TFE tumorsphere formation efficiency
Rostoker et al. Breast Cancer Research  (2016) 18:51 Page 5 of 12
control and CD24- IGF1R-KD groups. In contrast, in the
CD24+ cells, IGF1R-KD abolished the capacity to generate
tumorspheres (Fig. 2c).
Knockdown of the IGF1R in CD24+ Mvt1 cells impairs
mammary tumor formation
Based on our in vitro results (Fig. 2b, c), we hypothesized
that IGF1R-KD suppresses the tumorigenic capacity of the
CD24+ Mvt1 cells. Hence, we compared tumor growth
rate following inoculation of CD24- control and CD24-
IGF1R-KD cells and following inoculation of CD24+
control and CD24+ IGF1R-KD cells into the mammary fat
pad of WT and MKR female mice. In both WT and MKR
mice, tumors developed with similar growth rates follow-
ing inoculation of either CD24- control or CD24- IGF1R-
KD cells, and as expected tumorgenicity was enhanced in
hyperinsulinemic MKR mice compared with WT mice
(Fig. 3a). On the other hand, inoculation of CD24+
IGF1R-KD cells resulted with significantly smaller tumors
compared to the CD24+ control tumors in both WT and
MKR mice (Fig. 3b). Tumor weights, at the termination of
the experiment, confirmed these findings (Fig. 3c, d).
These results were further confirmed with a different
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Fig. 3 Knockdown of IGF1R in CD24+ Mvt1 cells impairs mammary tumor formation. Cells were injected into the mammary fat pad of 8-week-old
WT and MKR female mice. Tumor volume (a, b) was monitored during 4.5 weeks and tumor weights (c, d) were measured at necropsy. Tumor
lysates from WT (e) and MKR (g) mice were separated by SDS-PAGE, and IGF1R levels were assessed using Western blotting. f, h Relative expression
was quantified by densitometric analysis and is presented as a fold change compared with the control group. Equal loading of proteins
was demonstrated by immunoblotting with an antibody directed against β-actin. Mann-Whitney test was performed to compare the difference
between the control tumors and IGF1R-KD tumors, *P < 0.05, and difference between WT and MKR tumors #P < 0.05. IGF1R insulin-like growth factor
receptor, KD knockdown
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Figure S1A-E). Next, tumors were lysed and subjected
to Western blot analysis, which confirmed a significant
reduction in IGF1R expression in the CD24+ IGF1R-KD
tumors compared to the CD24+ control tumors (approxi-
mately 73 % and approximately 53 % in the WT mice
(Fig. 3e, f) and MKR mice (Fig. 3g, h) respectively). It is im-
portant to note that pAkt levels and pERK levels were not
different between the groups (data not shown). This may
be attributed to several endogenous factors that can acti-
vate both the PI3K/Akt pathway and the MAPK pathway,
or alternatively, these pathways are dynamic and the results
observed are representative of a specific time point.
SLPI is downregulated and CTGF is upregulated following
IGF1R-KD in CD24+ mouse and human cells
In order to identify transcripts that may be elucidated
for the specific effect of IGF1R on CD24+ tumorigenic
capacity we screened by qtPCR analysis several tran-
scripts that are associated with tumor growth and me-
tastasis. Our results indicate significant changes in two
transcripts with opposite effects on tumor growth. Con-
nective tissue growth factor (CTGF) has been suggested
as a tumor suppressor in human breast cancer [27] and
the secretory leukocyte protease inhibitor (SLPI) that en-
hances tumor aggressiveness through vascular mimicry
[28]. CTGF mRNA expression was significantly upregu-
lated in the CD24+ IGF1R-KD tumors compared with
the control tumors (>5-fold and >9-fold in the WT mice
and MKR mice respectively (Fig. 4a, b)). On the other
hand, SLPI expression was significantly down-regulated
in the CD24+ IGF1R-KD tumors by >15 fold in the WT
mice and by >9 fold in the MKR mice (Fig. 4a, b). SLPI
protein levels were significantly reduced by approxi-
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Fig. 4 IGF1R-KD induces SLPI downregulation and CTGF upregulation in CD24+. SLPI and CTGF mRNA levels were determined by qRT-PCR
analysis in WT (a) and MKR (b) tumors. Tumor lysates from WT (c) and MKR (e) mice were separated by SDS-PAGE, and SLPI levels were assessed
using Western blotting. d, f Relative expression was quantified by densitometric analysis and is presented as a fold change compared with the
control group. Equal loading of proteins was demonstrated by immunoblotting with an antibody directed against β-actin. g, h qRT-PCR analysis
of SLPI and CTGF in vitro. Mann-Whitney test was performed to compare the difference between the control group and IGF1R-KD group,
*P < 0.05, **P < 0.005, ***P < 0.001. CTGF connective tissue growth factor, IGF1R insulin-like growth factor receptor, KD knockdown, mRNA
messenger RNA, SLPI secretory leukocyte protease inhibitor
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with the control tumors in both WT (Fig. 4c-d) and
MKR mice (Fig. 4e-f ).
In order to confirm that these effects are a direct result
of IGF1R downregulation and are specific to the CD24+
cells, we compared the mRNA levels of these two tran-
scripts in vitro. Our results, confirmed that the expression
SLPI and CTGF is altered following IGF1R-KD. CD24+
IGF1R-KD cells displayed reduced SLPI levels (>2-fold)
and elevated CTGF levels (2.5-fold) (Fig.4g) compared to
the CD24+ control cells. These effects were specific to the
CD24+ cells, since IGF1R-KD had no effect on either of
these transcripts in the CD24- cells (Fig. 4h). These results
were further validated with the second construct against
the IGF1R (Additional file 2: Figure S2). Additionally, we
demonstrated that in the CD24+ MCF7 cell line IGF1R-
KD results in an approximately 52 % reduction in SLPI
mRNA expression as observed following IGF1R-KD in the
Mvt-1 CD24+ cells (Additional file 3: Figure S3A, B).
IGF1R-KD enhances CD24+ cancer cell plasticity in vivo
Recently, we have demonstrated a direct plasticity process
whereby CD24+ cells differentiate in vivo into CD24- cells
[19]. Based on the in vitro results (Fig. 2c) we hypothesized
that IGF1R is involved in this process. To examine this,
CD24+ control and CD24+ IGF1R-KD cells were injected
into the mammary fat pad of WT and MKR mice, and
tumors were allowed to grow for five weeks. At sacrifice,
tumors were dissociated into single cells and cancer cells
were FACS analyzed (based on their GFP expression) for
CD24 expression (Fig. 5a). As expected, direct plasticity to-
ward the CD24- phenotype was observed in both control
and IGF1R-KD groups in WTand in the MKR mice follow-
ing implantation of CD24+ cells (Fig. 5b). IGF1R-KD signifi-
cantly enhanced this differentiation process, as shown by
control tumors from WT mice that were comprised of
approximately 64 % CD24+ cells whereas only approxi-
mately 10 % were found to be CD24+ following implant-
ation of CD24+ IGF1R-KD cells (Fig. 5c). Similar results
were shown in the MKR tumors, where approximately
73 % of the cancer cells were CD24+ following implantation
of the CD24+ control cells, and only approximately 10 %
were CD24+ in the CD24+ IGF1R-KD tumors (Fig. 5c).
We further demonstrate that this differentiation process



































CD24+ control CD24+ IGF1R-KD CD24+ control CD24+ IGF1R-KD
a
Fig. 5 IGF1R-KD enhances CD24+ cancer cells plasticity in vivo. a Experimental strategy scheme is presented. CD24+ control or CD24+ IGF1R-KD
cells were injected into the mammary fat pads, after 4 weeks, tumors were harvested and CD24 expression was evaluated. b CD24 expression in
GFP-expressing cancer cells from mammary tumors was determined by FACS analysis. c Comparison of CD24+ population between control and
IGF1R-KD tumors in WT and MKR mice. Mann-Whitney test was performed to compare between control and IGF1R-KD tumors, ***P < 0.001. FACS
fluorescence-activated cell sorting, GFP green fluorescent protein, IGF1R insulin-like growth factor receptor, KD knockdown
Rostoker et al. Breast Cancer Research  (2016) 18:51 Page 8 of 12
significantly enhanced as a result of the tumor microenvir-
onment; the distribution of CD24- and CD24+ subsets was
not affected in vitro as a result of the IGF1R-KD (Additional
file 4: Figure S4).
IGF1R-KD significantly reduced the metastatic capacity of
CD24+ cells
We used the tail vein metastasis assay to determine the
effect of IGF1R-KD in both subsets of cancer cells (Fig. 6a).
Inoculation of each cell subset into the tail vein of WT
mice revealed high metastatic capacity for the CD24+
control cells with approximately eight lesions per lung,
whereas no lesions were found following CD24- control
cells inoculation (Fig. 6a, b). IGF1R-KD abolished CD24+
metastatic capacity, since no lesions were found following
inoculation of the CD24+ IGF1R-KD cells. These results
were further confirmed with the second construct against
the IGF1R (Additional file 5: Figure S5).
Discussion
Over the past few decades, findings regarding the role of
the IGF1R in cancer have continued to accumulate. The
IGF1R promotes cancer cell proliferation and survival
and, on the other hand, prevents apoptosis [1, 29, 30].
Moreover, the importance of the IGF1R in establishing
and maintaining a transformed phenotype was well
described [31, 32]. These evidences positioned the IGF1R
as a promising target for treating cancer. Hence, investiga-
tors along with pharmaceutical companies invested great
efforts in developing therapeutic strategies toward the IGF
system and specifically toward the IGF1R. Despite the
great success in preclinical studies, results from recent
and ongoing clinical trials have been distinctly disappoint-
ing [10]. It has become clear that predictive biomarkers
are required in order to select patients who would benefit
from anti-IGF1R therapy. In this study, we suggest that
CD24 cell surface expression in cancer cells may predict
sensitivity to anti-IGF1R therapy. Our results demonstrate
that IGF1R-KD specifically in CD24+ cancer cells alters
their morphology and phenotype and, more importantly,
markedly inhibited their tumorigenic capacity.
In the current study, we demonstrate that IGF1R-KD
had minimal effect on mammary tumors that formed by







































Fig. 6 IGF1R-KD significantly reduced the metastatic capacity of CD24+ cells. a Experimental strategy scheme is presented. b Representation of
lung metastasis following 4 weeks of 10,000 cells inoculation into the tail vein of the WT mice. c Average of macrometastasis per lung in each
group is displayed in the bar graph. Mann-Whitney test performed to compare the difference between the groups. **P < 0.005. IGF1R insulin-like
growth factor receptor, KD knockdown
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we found that the Mvt1 cells are comprised of two sub-
populations that differ by their CD24 cell surface expres-
sion, therefore termed CD24- and CD24+ cells [19].
Furthermore, our recent results, demonstrated that the
CD24+ subset is highly tumorigenic; these cells formed
rapidly growing mammary tumors and metastatic lesions
compared to their CD24- counterparts. Moreover, these
cells displayed early stem/progenitor properties in vitro
and in vivo [19]. Thus, we tested whether CD24 cell sur-
face expression could serve as a new marker to predict re-
sponse to anti-IGF1R therapy. We found that IGF1R-KD
induces a rounded epithelial morphology in the CD24+
cells that are normally characterized by mesenchymal-like
morphology, whereas CD24- subset was not affected by
the IGF1R-KD and maintained their epithelial morphology
despite the IGF1R-KD. The ability of cells to generate
tumorspheres when growing in suspension is a common
method to identify cells with stem/progenitor properties
[33]. The greater capacity of CD24+ cells to form
tumorspheres and the inability of CD24- cells to do so
was the most profound phenotype discrepancy between
these two populations in vitro [19]. Here we show that
IGF1R-KD completely abolished CD24+ cells capacity
to form tumorspheres.
In the pursuit of tailor-made medicine, the identifica-
tion of biomarkers that can imply who should receive
therapy and what therapy is greatly warranted [34, 35]
Following the disappointing results of anti-IGF1R phase
3 clinical trials in unselected patients, the search for pre-
dictive biomarkers that can identify suitable patients
who can benefit from anti-IGF1R therapy is now under
intensive investigation [10]. In order to further investigate
whether CD24 cell surface expression could implicate
tumor sensitivity to anti-IGF1R therapy, we inoculated
CD24- and CD24+ cells with and without IGF1R-KD into
the mammary fat pad of WT and the hyperinsulinemic
MKR female mice. In accordance with our in vitro results,
IGF1R-KD cells had a dramatic effect specifically on the
CD24+ tumors. CD24+ IGF1R-KD cells formed signifi-
cantly smaller tumors compared with the control CD24+,
cells whereas IGF1R-KD had no effect on CD24- tumor
growth. Western blot analysis confirmed significant reduc-
tion of the IGF1R in both CD24- and CD24+ tumors com-
pared to the control tumors. It is important to note that
the PI3K/Akt pathway and MAPK pathway failed to show
a reduction, this may be attributing to other endogenous
factors which can activate both pathways, and alterna-
tively, this can reflect the specific time point of sacrifice
since this protein modification is dynamic.
SLPI is a protease inhibitor and mediates a broad
array of activities that may not be related to its antiprotease
functions [36], including several malignancy-promoting
functions [37]. In the search for proteins that en-
hance tumor formation and metastasis, Wagenblast et al,
identified SLPI as a driver of metastatic formation in a
mouse model for breast cancer. Additionally, SLPI
emerged as the most significantly gene in human breast
cancer patients that had lung-metastatic relapses [28].
Using RNA-seq analysis, we have identified SLPI among
the top three upregulated genes in the highly tumorigenic
CD24+ Mvt1 cell subset [19], and suggests that SLPI may
play a role in the more aggressive cancers derived from
CD24+ cells. Taken together we hypothesized that IGF1R-
KD in the CD24+ significantly attenuates the tumorigenic
capacity by regulating SLPI levels. Our results, confirmed
a significant reduction in SLPI expression specifically in
the CD24+ IGF1R-KD tumors compared with CD24+ con-
trol tumors. However, SLPI levels were comparable be-
tween CD24- control and CD24- IGF1R-KD tumors. We
screened several other candidates that may elucidate the
specific antitumorigenic effect of IGF1R-KD in the CD24+
tumors. We identified a significant upregulation in CTGF,
specifically in the CD24+ IGF1R-KD tumors. CTGF is a
member of the CCN family of proteins that are involved
in adhesion, apoptosis, extracellular matrix production,
and growth arrest of multiple cell types; this is mostly at-
tributed to their ability to interact and activate integrins
[27, 38]. Though the role the CCN proteins play in cancer
is controversial, analysis of 122 human breast tumors sug-
gested CTGF as a tumor suppressor [27]. We further
demonstrated that this effect is not restricted to the tumor
process and that SLPI and CTGF expression is directly
regulated by IGF1R. QRT-PCR analysis of CD24+ cells in
vitro following IGF1R-KD demonstrated that IGF1R
downregulation results with a profound reduction in SLPI
levels and upregulation in CTGF levels. In accordance
with our in vivo results IGF1R-KD had no effect on both
SLPI and CTGF mRNA levels in the CD24- subset. The
altered expression observed for both SLPI and CTGF
following IGF1R-KD were dramatically greater in vivo.
SLPI levels were reduced by approximately 10-fold in the
CD24+ IGF1R-KD tumors (compared with the CD24+ con-
trol tumors), whereas the in vitro results demonstrated
only a 50 % reduction. These in vivo changes in SLPI levels
matched the difference in SLPI levels between CD24+ and
CD24- cells [19]. Recently, we demonstrated that CD24+
cells differentiate in vivo in response to intratumor stimuli
into distinct CD24- cell population [19]. This, along with
recent reports that suggest a role for the IGF1R in main-
taining stemness [20], encouraged us to test whether
IGF1R-KD induced rapid differentiation in vivo toward the
CD24- phenotype. FACS analysis of cancer cells dissociated
from CD24+ control and IGF1R-KD tumors, revealed that
IGF1R is essential for the maintenance of stem/progeni-
tors-like cancer cells that fuel the cancer process as re-
cently described [19, 39].
There is some “heterogeneity” in the results of pre-
clinical and clinical studies regarding anti-IGF1R therapies.
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Burtrum et al, demonstrated that IGF1R inhibition in vivo,
resulted in a significant reduction in tumor growth follow-
ing inoculation of the adenocarcinoma MCF7 cell line [5].
In contrast, primary tumors formed by MDA-MB-231 cells
with IGF1R-KD grew as rapidly as the control tumors [40].
It is important to note that these cells known as CD24- cells
[41]. Our results indicate that CD24 expression in breast
tumors may indicate sensitivity to anti-IGF1R therapy.
Hence, to further investigate this, we determined CD24 cell
surface expression in the mammary carcinoma MCF7 cell
line. We found in accordance with previous studies [41, 42]
that MCF7 are CD24+ cells. To test the feasibility of our re-
sults in CD24+ human breast cancer cells, we downregu-
lated IGF1R in the MCF7 cells and identified a marked
reduction in SLPI levels.
Dissemination of tumors cells from the primary tu-
mors and colonialization in distant sites, accounts for
the vast majority of cancer-related death [43]. Using
the tail vein metastasis assay we demonstrated that
IGF1R-KD abolished the metastatic capacity of the
Mvt1 CD24+ cells.
Conclusions
Taken all together, our results here indicate that cell
surface expression of CD24 in breast tumor cells may
serve as a valuable biomarker to identify breast cancer pa-
tients that will benefit from anti-IGF1R therapy. More-
over, we demonstrate that IGF1R play a significant role in
maintaining cancer stem/progenitor-like phenotype of
cancer cells, and these results in rapid tumor growth.
Moreover, we identified that IGF1R regulates SLPI and
CTGF expression specifically in CD24+ cells. Further re-
search with different types of breast cancer models and
different anti-IGF1R strategies are required in order to
further determine the feasibility of these results.
Additional files
Additional file 1: Figure S1. IGF1R-KD in CD24+ Mvt1 cells impairs
mammary tumor formation. (A) Western blot analysis of IGF1R expression
in Mvt1 cells infected with control or IGF1R shRNA as indicated. (B) Protein
expression was quantified relative to β-actin expression by densitometric
analysis. (C) Control and IGF1R-KD Mvt-1 cells were FACS sorted into pure
CD24- and CD24+ cell populations. (D) Control and IGF1R-KD cells were
injected into the fourth mammary fat pad of 8-week-old virgin FVB/N mice
(50,000 cells/mouse) and tumor volume was measured during a 5-week
period (E) Tumor weights were measured at necropsy. Mann-Whitney
test performed to compare the difference between the groups. *P < 0. 05,
**P < 0.005. (PPTX 107 kb)
Additional file 2: Figure S2. IGF1R-KD induces SLPI downregulation
and CTGF upregulation in CD24+. QRT-PCR analysis of SLPI and CTGF in
vitro in Mvt1 cells. (PPTX 46 kb)
Additional file 3: Figure S3. IGF1R-KD in the CD24+ MCF7 cell line,
results in reduced SLPI expression. (A) FACS analysis of CD24 cell surface
expression in MCF7 cells. (B) Western blot analysis of IGF1R expression in
MCF7 cells infected with control or IGF1R shRNA as indicated. (c) QRT-PCR
analysis of SLPI in vitro. (PPTX 1550 kb)
Additional file 4: Figure S4 Cell surface expression of CD24 and CD49f.
A FACS dot plot showing CD24 and CD49f cell surface expression in
control and IGF1R-KD Mvt1 cells. (PPTX 72 kb)
Additional file 5: Figure S5 IGF1R-KD significantly reduced the
metastatic capacity of CD24+ cells. (A) Representation of lung metastasis
following 4 weeks of 10,000 cells inoculation into WT mice tail vein. (B)
Average of macrometastasis per lung in each group is displayed in the
bar graph. Mann-Whitney test performed to compare the difference
between the groups. **P < 0.005. (PPTX 537 kb)
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